mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
0.048 |
0.1 |
mRNA |
JQ-1:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.057 |
0.1 |
mRNA |
AM-580 |
CTRPv2 |
pan-cancer |
AAC |
-0.063 |
0.1 |
mRNA |
tanespimycin:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.054 |
0.1 |
mRNA |
selumetinib:JQ-1 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.057 |
0.1 |
mRNA |
Parthenolide |
CTRPv2 |
pan-cancer |
AAC |
-0.063 |
0.1 |
mRNA |
BRD-K41334119 |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.1 |
mRNA |
HC-067047 |
CTRPv2 |
pan-cancer |
AAC |
-0.063 |
0.1 |
mRNA |
AZD6244 |
UHNBreast |
pan-cancer |
AAC |
0.46 |
0.1 |
mRNA |
BRD-K27188169:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.087 |
0.1 |